Private Companies Invested in Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Copped the Brunt of Last Week's CN¥2.0b Market Cap Decline

Simply Wall StOct 10 18:19 ET

Hubei Biocause Pharmaceutical's Insurance Unit Logs 29 Billion Yuan Premium Income in January-August Period; Shares Down 3%

MT NewswiresSep 17 22:17 ET

Hubei Biocause Pharmaceutical (000627.SZ) subsidiary China Best Life Insurance Co., Ltd. accumulated premium income of approximately 29.03 billion yuan from January to August.

Hubei Biocause Pharmaceutical (000627.SZ) announced that its subsidiary, China Best Life Insurance Co., Ltd., has...

Zhitong FinanceSep 17 03:59 ET

Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Doing What It Can To Lift Shares

Simply Wall StSep 4 23:00 ET

Hubei Biocause Pharmaceutical (000627.SZ): No share buyback transaction has been conducted.

On September 2, GeLongHui announced that as of August 31, 2024, Hubei Biocause Pharmaceutical (000627.SZ) has repurchased a total of 0 shares of the company through the special securities account for share repurchase, accounting for 0.00% of the total share capital of the company.

Gelonghui FinanceSep 2 06:40 ET

Tianmao Group: Guohua Life 2024 Semi-Annual Report

SZSIAug 30 12:00 ET · Announcements